Amgen Inc. (AMGN) Shares Bought by Dubuque Bank & Trust Co.
Dubuque Bank & Trust Co. raised its stake in Amgen Inc. (NASDAQ:AMGN) by 8.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 78,713 shares of the medical research company’s stock after buying an additional 6,228 shares during the period. Amgen accounts for 2.9% of Dubuque Bank & Trust Co.’s holdings, making the stock its 4th largest position. Dubuque Bank & Trust Co.’s holdings in Amgen were worth $12,914,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in AMGN. Thomas J. Herzfeld Advisors Inc. acquired a new stake in Amgen during the fourth quarter valued at $102,000. Focused Wealth Management Inc increased its position in shares of Amgen by 248.0% in the fourth quarter. Focused Wealth Management Inc now owns 870 shares of the medical research company’s stock worth $127,000 after buying an additional 620 shares in the last quarter. Northwest Quadrant Wealth Management LLC purchased a new position in shares of Amgen during the fourth quarter worth approximately $157,000. Cable Hill Partners LLC increased its position in shares of Amgen by 2.7% in the first quarter. Cable Hill Partners LLC now owns 982 shares of the medical research company’s stock worth $161,000 after buying an additional 26 shares in the last quarter. Finally, Cribstone Capital Management LLC increased its position in shares of Amgen by 2.3% in the first quarter. Cribstone Capital Management LLC now owns 1,113 shares of the medical research company’s stock worth $182,000 after buying an additional 25 shares in the last quarter. Institutional investors and hedge funds own 78.86% of the company’s stock.
Shares of Amgen Inc. (AMGN) opened at 162.42 on Friday. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $184.21. The firm has a market cap of $119.44 billion, a PE ratio of 15.43 and a beta of 1.37. The firm’s 50-day moving average price is $160.16 and its 200 day moving average price is $160.84.
Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, April 26th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.00 by $0.15. Amgen had a return on equity of 29.37% and a net margin of 34.42%. The business had revenue of $5.46 billion for the quarter, compared to the consensus estimate of $5.60 billion. During the same period last year, the business earned $2.90 earnings per share. The firm’s revenue for the quarter was down 1.1% compared to the same quarter last year. Equities analysts anticipate that Amgen Inc. will post $12.43 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Amgen Inc. (AMGN) Shares Bought by Dubuque Bank & Trust Co.” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/06/18/dubuque-bank-trust-co-raises-stake-in-amgen-inc-amgn-updated.html.
Several research firms have commented on AMGN. Mizuho set a $195.00 price objective on Amgen and gave the stock a “buy” rating in a research report on Saturday, May 6th. Morgan Stanley upped their target price on Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 13th. Cowen and Company reaffirmed an “outperform” rating and set a $209.00 target price on shares of Amgen in a research note on Wednesday, April 19th. BMO Capital Markets reissued a “buy” rating and issued a $198.00 price objective (down from $200.00) on shares of Amgen in a research note on Monday, May 22nd. Finally, Sanford C. Bernstein set a $164.00 price objective on Amgen and gave the company a “hold” rating in a research note on Thursday, June 8th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Amgen currently has a consensus rating of “Buy” and a consensus price target of $185.49.
In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the firm’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total transaction of $451,156.80. Following the completion of the transaction, the senior vice president now owns 24,214 shares in the company, valued at $3,738,641.60. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.20% of the stock is owned by company insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.